Research Signal – Source date 2021-02-04
Stopping a cancer cell from dividing sounds like an obvious therapeutic goal. But some cells can enter a state called senescence, in which they stop multiplying while remaining biologically active. They may continue releasing signals that alter nearby cells and tissues. In myeloid blood cancers, that creates a difficult question: should treatment reinforce the growth arrest, remove the senescent cells, or address the surrounding marrow environment as well?
A review published on February 4, 2021, examines that problem across myeloid malignancies, including myelodysplastic syndromes, myeloproliferative neoplasms, and acute myeloid leukemia. It brings together molecular mechanisms, laboratory experiments, animal findings, and clinical examples. Its contribution is not evidence of one validated treatment sequence. It is a focused explanation of why arrested growth and selective cell clearance represent different therapeutic ideas.
Senescence stops division without switching the cell off
Normal human somatic cells have a limited capacity to divide. With repeated replication, telomeres shorten, and cells can eventually reach replicative senescence. Senescence can also arise prematurely after signals such as oncogene activity or DNA damage. In either case, the central feature is a durable cell-cycle arrest rather than immediate cell death.
This state differs from quiescence. A quiescent cell is resting in the G0 phase and may resume proliferation after an appropriate stimulus. A senescent cell is generally unable to respond to ordinary growth signals and remains arrested around the G1/S transition. The review also notes an important qualification for cancer biology: under some conditions, senescent tumor cells can re-enter the cell cycle. That possibility makes a growth-arrest label less reassuring than it might first appear.
One molecular brake involves the retinoblastoma protein, or RB. When RB is hypophosphorylated, it binds the transcription factor E2F and suppresses genes that promote entry into the DNA-synthesis phase of the cell cycle. The RB/E2F complex also helps recruit enzymes that impose repressive chromatin marks on those gene promoters. The result is a more stable block on S-phase activity.
The arrested cell is not necessarily silent. Senescent cells can release chemokines, inflammatory cytokines, proteases, growth factors, and other molecules through what researchers call the senescence-associated secretory phenotype, or SASP. Its composition varies substantially with cell type and the stimulus that produced senescence. Signals linked to damaged DNA can activate the cGAS–STING pathway and contribute to inflammatory gene expression, including through NF-κB and IRF3. The important point for treatment is that the growth-control mechanism and the secretory behavior are related but distinct features.
The marrow can become part of the disease
The review describes a sequence in which acute myeloid leukemia cells influence cells that are not themselves leukemic. Through NOX2-derived superoxide production, AML cells can induce p16INK4a-associated senescence in bone marrow stromal cells. Those stromal cells then release SASP factors, especially IL-6 and MIP-3α, that support leukemia-cell survival.
This changes the treatment problem. A therapy directed only at dividing leukemia cells may leave behind a surrounding population whose altered secretions help maintain the malignant cells. The marrow is not simply a passive container for leukemia; its cellular environment can participate in disease-supporting communication.
Treatment can add another layer. The review reports that purine analogs and anthracyclines can produce therapy-associated senescence in leukemia cells and in healthy parts of the bone marrow microenvironment. Senescent cells can release CCL2, which attracts CCR2-positive immature myeloid cells. In a tumor-free setting, those cells may mature into dendritic cells, macrophages, or neutrophils and participate with T cells and natural killer cells in senescence surveillance.
In the presence of tumor-derived signals, however, the immature cells may remain in an immunosuppressive state. The review describes them as tumor-associated myeloid-derived suppressor cells, or MDSCs, which can weaken immune activity and help create conditions in which tumor cells persist. An intervention that interrupts the CCL2/CCR2 axis was therefore discussed as a possible way to alter the leukemia microenvironment. In an AML mouse model, the CCL2-blocking Spiegelmer mNOX-E36 reduced infiltration by immunosuppressive M2-like macrophages. That result belongs to an animal setting and does not establish a general clinical strategy.
Different treatments aim at different cellular problems
The review groups potential approaches according to what they are trying to do. One approach is to reinforce a growth-control program so malignant cells stop proliferating. Another is to remove cells that have entered a harmful senescent state. A third may affect the environment that shelters them. These aims should not be treated as interchangeable.
Palbociclib illustrates the first approach. As a CDK4/6 inhibitor, it can block cancer-cell proliferation and induce senescence through the combined effects of CDK inhibition and disrupted proteasomal homeostasis. In the evidence summarized by the review, palbociclib inhibited AML-cell proliferation in vitro in a dose-dependent manner. Laboratory work also found a synergistic effect when it was combined with FLT3 inhibitors in FLT3-mutated AML cells. These are cell-based findings, useful for identifying a possible vulnerability but not a patient treatment result.
Navitoclax illustrates the second approach. It inhibits several anti-apoptotic BCL-2-family proteins, including BCL-XL, BCL-2, and BCL-W. The review describes it as a senolytic in aged mice and in younger mice exposed to irradiation, where it selectively eliminated senescent cells. The setting matters: those findings come from animal models rather than from a demonstrated senolytic treatment for all myeloid cancers.
The same target that makes a senolytic attractive can also create a safety problem. Platelets depend on BCL-XL for survival, so navitoclax can cause thrombocytopenia. This example shows why “remove senescent cells” is not enough as a therapeutic description. A useful treatment would need to distinguish a harmful senescent population from normal cells that depend on the same survival pathway.
The review also discusses venetoclax, a BCL-2 inhibitor, including its combination with azacitidine in elderly patients with AML. The review described promising clinical activity for that combination in a population with historically poor outcomes and linked it to inhibition of energy metabolism in leukemia stem cells. However, clinical activity of a drug combination does not by itself demonstrate that senescent-cell clearance caused the benefit. A treatment can work through several biological processes at once, and the patient evidence summarized here does not validate a sequence in which senescence is first induced and then selectively removed.
A senescence marker is not a treatment test
Before researchers can eliminate harmful senescent cells, they need a dependable way to recognize them. The review describes senescence-associated beta-galactosidase, or SA β-gal, as a widely used marker in cells and tissues. Its detection at pH 6 can support identification of senescence, especially alongside other features such as phosphorylated histone H2AX or senescence-associated heterochromatin foci marked by H3K9me3.
SA β-gal alone has a limitation: the review notes that nonspecific expression has also been observed in immortalized tumor cell lines. A positive signal therefore does not prove that every marked cell is senescent, that the cells are driving disease, or that a drug has removed them selectively. Detection and clearance are separate scientific tasks.
The distinction becomes especially important in the marrow, where treatment-associated senescence may involve both leukemia cells and healthy supporting cells. Eliminating a marker-positive population without understanding its identity could damage normal hematopoiesis or produce toxicity without addressing the cells that sustain leukemia. The platelet problem with navitoclax makes the broader principle concrete: a molecular target may be present in a harmful population and in essential normal cells at the same time.
For that reason, anticancer activity, senolytic action, and tolerable treatment should be reported as different claims. A laboratory result can show that a drug slows AML-cell growth. An animal experiment can show that a compound removes a senescent population under particular conditions. A patient study can show clinical activity. None of those observations automatically supplies the others, and results from one myeloid disease, cell type, or model cannot be extended to every senescent cell or blood cancer.
What this could mean for leukemia treatment
The February 2021 perspective points toward a conditional treatment goal: control malignant cells while limiting the persistent damage that senescent populations may cause in the marrow environment. Reaching that goal would require therapies that identify the relevant cells accurately, spare normal blood-forming cells and platelets, and demonstrate their mechanism and benefit in patients. The review’s examples show why those requirements are difficult, not that they have already been met.
For people with myeloid blood cancers, the longer-term possibility is more durable disease control with less persistent disruption of the marrow environment, provided harmful senescent populations can be targeted selectively and patient studies establish benefit. The evidence summarized in this review supports pursuing that possibility without prescribing a drug combination or assuming that inducing senescence and clearing senescent cells is already a validated clinical sequence.
Key Sources
- Primary source: Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies.
DOI or Journal Page · Review or Meta-Analysis · 2021-02-04
Keep exploring